These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33914050)

  • 1. Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014.
    Wright JD; Chen L; Tergas AI; Melamed A; St Clair CM; Hou JY; Khoury-Collado F; Gockley A; Accordino M; Hershman DL
    JAMA Netw Open; 2021 Apr; 4(4):e218373. PubMed ID: 33914050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
    Qin J; Shahangian S; Saraiya M; Holt H; Gagnon M; Sawaya GF
    Gynecol Oncol; 2021 Nov; 163(2):378-384. PubMed ID: 34507826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of cervical cancer screening among Medicaid beneficiaries.
    Dillon J; Chen L; Melamed A; St Clair CM; Hou JY; Khoury-Collado F; Gockley A; Accordino M; Hershman DL; Wright JD
    BJOG; 2022 Jun; 129(7):1104-1111. PubMed ID: 34882962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
    Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
    J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
    Kulkarni A; Chen L; Gockley A; Khoury-Collado F; Hou J; Clair CST; Melamed A; Hershman DL; Wright JD
    Gynecol Oncol; 2023 Aug; 175():53-59. PubMed ID: 37327539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis.
    Sawaya GF; Sanstead E; Alarid-Escudero F; Smith-McCune K; Gregorich SE; Silverberg MJ; Leyden W; Huchko MJ; Kuppermann M; Kulasingam S
    JAMA Intern Med; 2019 Jul; 179(7):867-878. PubMed ID: 31081851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination.
    Grimes DR; Corry EMA; Malagón T; O'Riain C; Franco EL; Brennan DJ
    JAMA Netw Open; 2021 Jun; 4(6):e2115321. PubMed ID: 34190993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated With Guideline-concordant and Excessive Cervical Cancer Screening: A Mixed Methods Study.
    Perkins RB; Fuzzell L; Lake P; Brownstein NC; Fontenot HB; Michel A; Whitmer A; Vadaparampil ST
    Womens Health Issues; 2024; 34(3):257-267. PubMed ID: 38383228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
    Kim JJ; Burger EA; Regan C; Sy S
    JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific 3-year cumulative risk of cervical cancer and high-grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting.
    Ge Y; Christensen PA; Luna E; Armylagos D; Xu J; Hsu JW; Zhou H; Schwartz MR; Mody DR
    Cancer Cytopathol; 2019 Dec; 127(12):757-764. PubMed ID: 31589379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening.
    MacLaughlin KL; Jacobson RM; Radecki Breitkopf C; Wilson PM; Jacobson DJ; Fan C; St Sauver JL; Rutten LJF
    J Womens Health (Larchmt); 2019 Feb; 28(2):244-249. PubMed ID: 30614380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program.
    Machalek DA; Roberts JM; Garland SM; Thurloe J; Richards A; Chambers I; Sivertsen T; Farnsworth A
    Med J Aust; 2019 Aug; 211(3):113-119. PubMed ID: 31168828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Management of Abnormal Cervical Cancer Screening Results and Concordance with Guideline Recommendations in Three US Healthcare Settings.
    Cheng D; Rieu-Werden ML; Lykken JM; Werner CL; Feldman S; Silver MI; Atlas SJ; Tiro JA; Haas JS; Kamineni A
    Cancer Epidemiol Biomarkers Prev; 2024 Jul; 33(7):912-922. PubMed ID: 38652505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
    Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
    Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triage human papillomavirus testing for cytology-based cervical screening in women of different ages in primary hospitals: A retrospective clinical study.
    Zhang YY; Xu XQ; Zhang D; Wu J; Zhang HX
    Medicine (Baltimore); 2020 Sep; 99(38):e22320. PubMed ID: 32957398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
    Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
    Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
    Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
    Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.